131 related articles for article (PubMed ID: 12551837)
1. The feasibility of reduced-intensity allogeneic hematopoietic stem cell transplantation from a related donor with HLA one-antigen with or without one-allele mismatch.
Nakai K; Mineishi S; Kami M; Kanda Y; Tanosaki R; Takaue Y
Haematologica; 2003 Jan; 88(1):115-7. PubMed ID: 12551837
[No Abstract] [Full Text] [Related]
2. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
3. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors.
Greinix HT; Faé I; Schneider B; Rosenmayr A; Mitterschiffthaler A; Pelzmann B; Kalhs P; Lechner K; Mayr WR; Fischer GF
Bone Marrow Transplant; 2005 Jan; 35(1):57-62. PubMed ID: 15531903
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation.
Wirk B; Klumpp TR; Ulicny J; Herman JH; Gajewski JL; Martin ME; Emmons RV; Mangan KF
Transfusion; 2008 Jan; 48(1):163-8. PubMed ID: 17900280
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Kusumi E; Kami M; Yuji K; Hamaki T; Murashige N; Hori A; Kojima R; Kishi Y; Kim SW; Ueyama J; Miyakoshi S; Tanosaki R; Morinaga S; Mori S; Heike Y; Muto Y; Masuo S; Taniguchi S; Takaue Y
Bone Marrow Transplant; 2004 Apr; 33(7):697-702. PubMed ID: 14755317
[TBL] [Abstract][Full Text] [Related]
6. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
[TBL] [Abstract][Full Text] [Related]
7. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
8. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Mehta J; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Singhal S
Bone Marrow Transplant; 2006 Jul; 38(2):95-100. PubMed ID: 16751789
[TBL] [Abstract][Full Text] [Related]
9. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
10. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
[TBL] [Abstract][Full Text] [Related]
12. Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.
Hauzenberger D; Schaffer M; Ringdén O; Hassan Z; Omazic B; Mattsson J; Wikström AC; Remberger M
Tissue Antigens; 2008 Dec; 72(6):549-58. PubMed ID: 19000143
[TBL] [Abstract][Full Text] [Related]
13. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
14. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
Kiehl MG; Kraut L; Schwerdtfeger R; Hertenstein B; Remberger M; Kroeger N; Stelljes M; Bornhaeuser M; Martin H; Scheid C; Ganser A; Zander AR; Kienast J; Ehninger G; Hoelzer D; Diehl V; Fauser AA; Ringden O
J Clin Oncol; 2004 Jul; 22(14):2816-25. PubMed ID: 15254049
[TBL] [Abstract][Full Text] [Related]
15. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
[TBL] [Abstract][Full Text] [Related]
16. The clinical implications of HLA mismatches in unrelated donor haematopoietic cell transplantation.
Shaw BE
Int J Immunogenet; 2008 Aug; 35(4-5):367-74. PubMed ID: 18976440
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation.
Danzer M; Polin H; Pröll J; Haunschmid R; Hofer K; Stabentheiner S; Hackl C; Kasparu H; König J; Hauser H; Binder M; Weiss R; Gabriel C; Krieger O
Transplantation; 2009 Aug; 88(4):528-32. PubMed ID: 19696636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]